Stock Price Quote

SUVEN LIFE SCIENCES LTD.

NSE : SUVENBSE : 530239ISIN CODE : INE495B01038Industry : Pharmaceuticals & DrugsHouse : Private
BSE134.205.65 (+4.4 %)
PREV CLOSE ( ) 128.55
OPEN PRICE ( ) 148.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 190971
TODAY'S LOW / HIGH ( )132.20 152.00
52 WK LOW / HIGH ( )83.27 169
NSE134.085.69 (+4.43 %)
PREV CLOSE( ) 128.39
OPEN PRICE ( ) 153.00
BID PRICE (QTY) 134.08 (6166)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4228484
TODAY'S LOW / HIGH( ) 132.01 153.00
52 WK LOW / HIGH ( )82.95 169.3
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 09-03 1989
Management Info
Venkateswarlu Jasti - Chairman Venkateswarlu Jasti - Managing Director
Registered Office

Address 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040- 23541142 /3315 / 23543311

Email info@suven.com

Website www.suven.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

08Jan Suven Life Sciences informs about cert
Suven Life Sciences has informed that the details of securities demateri..
03Dec Suven Life Sciences informs about news
Suven Life Sciences has enclosed copies of the newspaper advertisements,..
07Oct Suven Life Sciences informs about cert
Suven Life Sciences has informed that that the details of securities dem..
06Aug Suven Life Sciences informs about news
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosur..
13Jul Suven Pharmaceuticals informs about ap
Suven Pharmaceuticals has informed about appointment of Walker Chandiok..

Financials

in Millions
QTR Sep 24 ANNUAL 24
Net Profit-110.72-80.0799999999999
Gross Profit -110.72 -90.0999999999999
Operating Profit -96.01-98.0699999999999
Net Sales 25.73116.93

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  7043.70 (1.90%)
M.Cap ( in Cr)17609.25
Kwality Pharma (BSE)
peergroup  991.15 (2.14%)
M.Cap ( in Cr)1028.44
Shree Ganesh Remed. (BSE)
peergroup  701.15 (2.95%)
M.Cap ( in Cr)900.11
Piramal Pharma (BSE)
peergroup  232.45 (4.87%)
M.Cap ( in Cr)30817.02
Gufic Biosciences (BSE)
peergroup  475.90 (2.08%)
M.Cap ( in Cr)4772.21

Shareholding Pattern

PROMOTERS 70.27%
NON-INSTITUTION 28.34%
MUTUAL FUNDS/UTI 1.05%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Suven Life Sciences Ltd.

Suven Life Sciences Ltd. was incorporated in the year 1989. Its today's share price is 134.2. Its current market capitalisation stands at Rs 2926.55 Cr. In the latest quarter, company has reported Gross Sales of Rs. 116.93 Cr and Total Income of Rs.328.23 Cr. The company's management includes Sudha Rani Jasti, Vajja Sambasiva Rao, JAS Padmaja, Santanu Mukherjee, Seyed E Hasnain, Venkateswarlu Jasti, Venkateswarlu Jasti, Shrenik Soni.

It is listed on the BSE with a BSE Code of 530239 , NSE with an NSE Symbol of SUVEN and ISIN of INE495B01038. It's Registered office is at 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Karvy & Co, Tukaram & Co, Tukaram & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.